Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Jun R Chiong"'
Publikováno v:
International Journal of Nephrology and Renovascular Disease, Vol 2010, Iss default, Pp 51-60 (2010)
Savina Nodari1, Geoffrey T Jao2, Jun R Chiong31Division of Cardiology, University of Brescia, Brescia, Italy; 2Section of General Internal Medicine, Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA; 3Division of Cardiology, Loma
Externí odkaz:
https://doaj.org/article/581bb3a2136441bcb9ff5f4de644dff7
Autor:
Mark E. Dunlap, Paul J. Hauptman, Alpesh N. Amin, Sandra L. Chase, Joseph A. Chiodo, Jun R. Chiong, Joseph F. Dasta
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 8 (2017)
BackgroundHyponatremia (HN) occurs commonly in patients with acute heart failure and confers a worse prognosis. Current HN treatment varies widely, with no consensus. This study recorded treatment practices currently used for patients hospitalized wi
Externí odkaz:
https://doaj.org/article/99064c6d43694917996c5aa5358c3cbf
Autor:
Paul J. Hauptman, Alpesh Amin, Sandra L. Chase, Mark E. Dunlap, Jun R. Chiong, Joseph F. Dasta, Joseph Chiodo
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Hyponatremia ( HN ) occurs commonly in patients with acute heart failure and confers a worse prognosis. Current HN treatment varies widely, with no consensus. This study recorded treatment practices currently used for patients hospitalized
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82749300e94f18370eee8ac0da2e8ff0
https://doi.org/10.1161/jaha.116.005261
https://doi.org/10.1161/jaha.116.005261
Autor:
Rudell Christian, Jun R Chiong, Keith Friend, Joseph F. Dasta, Jay Lin, Irving B Cassidy, Melissa Lingohr-Smith
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 12:399-410
Tolvaptan is a member of a new class of drugs, called the vaptans, that antagonize receptors of the neurohormone arginine vasopressin. From a clinical perspective, tolvaptan has been shown to be efficacious in the treatment of hyponatremia, whether i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb19a7c9c0018be0b4898cb10a899ecf
https://doi.org/10.1586/erp.12.30
https://doi.org/10.1586/erp.12.30
Publikováno v:
Hospital Practice. 40:7-14
Two randomized clinical trials, the Study of Ascending Levels of Tolvaptan in Hyponatremia 1 and 2 (SALT-1 and SALT-2), showed that tolvaptan was an efficacious and safe therapy for the treatment of hyponatremic patients with the syndrome of inapprop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e25a963c7f725306ec9f1775f5821e4c
https://doi.org/10.3810/hp.2012.02.942
https://doi.org/10.3810/hp.2012.02.942
Autor:
Jun R. Chiong, Rebecca J Cheung
Publikováno v:
Clinical Cardiology. 33:345-352
Background Heart failure (HF) is a common condition associated with substantial cost, morbidity, and mortality. Because results of clinical trials in the acute decompensated heart failure (ADHF) setting have been mostly neutral, loop diuretics remain
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56c54611a28223554a3f84507f5110f6
https://doi.org/10.1002/clc.20771
https://doi.org/10.1002/clc.20771
Publikováno v:
Congestive Heart Failure. 16:170-174
Coronary artery bypass grafting (CABG) in patients with systolic heart failure (HF) carries high morbidity and mortality rates. Reducing perioperative mortality with beta-blockers (BBs) may help improve outcomes. Analysis of 4903 patients who underwe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::296b2c35adef9ef84d8697ac51918c80
https://doi.org/10.1111/j.1751-7133.2010.00146.x
https://doi.org/10.1111/j.1751-7133.2010.00146.x
Publikováno v:
Heart Failure Reviews. 15:293-304
N-terminal fragment of pro B-type natriuretic peptide (NT-proBNP) has emerged as an important adjunct in the management of heart failure (HF) and other cardiovascular diseases. NT-proBNP is a 76-amino acid peptide created during cleavage of the precu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a30cc34663681c96fac57f94271e5915
https://doi.org/10.1007/s10741-009-9142-1
https://doi.org/10.1007/s10741-009-9142-1
Autor:
Chandra K. Nair, Richard A. Dart, Stephen A. Geraci, Wilbert S. Aronow, Thomas Behrenbeck, Krishnaswami Vijayaraghavan, Jun R. Chiong, Ijaz A. Khan
Publikováno v:
International Journal of Cardiology. 124:6-21
Secondary hypertension affects a small but significant number of the hypertensive population and, unlike primary hypertension, is a potentially curable condition. The determinant for workup is dependent on the index of suspicion elicited during patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6f8acd6c6549db34e15c3ed913f915d
https://doi.org/10.1016/j.ijcard.2007.01.119
https://doi.org/10.1016/j.ijcard.2007.01.119
Publikováno v:
Journal of Cardiac Failure. 11:164-172
Background The incidence both of heart failure and atrial fibrillation is steadily increasing in the United States' population, and these conditions frequently coexist in the same patient. It is likely that the onset of one of these disorders leads t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5b024abaa432a4c47bae1027965e4cf
https://doi.org/10.1016/j.cardfail.2004.09.011
https://doi.org/10.1016/j.cardfail.2004.09.011